NRSNW 0.14 NeuroSense Therapeutics Ltd.
| Range: | 0.12-0.12 | Vol Avg: | 0 | Last Div: | 0 | Changes: | -0.02 |
| Beta: | 1.56 | Cap: | 0.02B | Currency: | USD | Exchange: | NASDAQ |
| Sector: | Healthcare | IPO: | Thu Jan 01 1970 | Empoloyees: | 18 | ||
| CUSIP: | M74240116 | CIK: | 0001875091 | ISIN: | IL0011811630 | Country: | IL |
| CEO: | Mr. Alon Ben-Noon | Website: | https://www.neurosense-tx.com | ||||
NeuroSense Therapeutics Ltd., a clinical-stage biotechnology company, focuses on discovering and developing treatments for debilitating neurodegenerative diseases in Israel. Its lead product candidate is PrimeC, a novel oral formulation for the treatment of amyotrophic lateral sclerosis. The company's preclinical pipeline product candidates include StabiliC for the treatment of Parkinson's disease; and CogniC for the treatment of Alzheimer's disease. NeuroSense Therapeutics Ltd. was incorporated in 2017 and is headquartered in Herzliya, Israel.
Stock Details
About The Monevue
The content provided on this site is for informational purposes only and does not constitute financial, investment, or professional advice. We are not registered investment advisors or financial planners, and we do not provide recommendations or advice on buying, selling, or holding any particular stocks or securities. Any investment decisions should be made based on your own research and consultation with a qualified financial professional. We are not responsible for any financial loss or damages incurred from reliance on the information provided on this site. Please invest responsibly and seek professional advice when needed.
• Powered by StackThrow